Lung Non-Small Cell Squamous Carcinoma clinical trials at UC Health
1 research study open to eligible people
open to all eligible people
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
at UC Davis UCSD